Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 3/20 | 0.54 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.54 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.46 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.46 |
| ▸ | IDH1 | O75874 | 1/20 | 0.44 |
| ▸ | AGXT | P21549 | 1/20 | 0.43 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.43 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.43 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.43 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.43 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2396236 | 0.86 | CYP2A6 (0.48) | CYP2A6ADRB2ASIC3LOXL2AGXT | |
| SCHEMBL10480282 | 0.83 | HDAC1 (0.42) | CYP2A6ADRB2IDH1HDAC1 | |
| SCHEMBL5691284 | 0.81 | CYP2A6 (0.51) | CYP2A6ADRB2ASIC3LOXL2IDH1 | |
| SCHEMBL2396391 | 0.80 | CYP2A6 (0.54) | CYP2A6ADRB2ASIC3LOXL2AGXT | |
| SCHEMBL1177008 | 0.77 | CYP2A6 (0.58) | CYP2A6ADRB2ASIC3LOXL2IDH1 | |
| SCHEMBL21400323 | 0.76 | CYP2A6 (0.53) | CYP2A6ADRB2ASIC3LOXL2IDH1 | |
| SCHEMBL14106983 | 0.74 | CYP2A6 (0.60) | CYP2A6ADRB2ASIC3LOXL2IDH1 | |
| SCHEMBL2396386 | 0.73 | LOXL2 (0.46) | LOXL2AGXTHDAC3HDAC1HDAC2 | |
| SCHEMBL7026250 | 0.73 | CYP2A6 (0.54) | CYP2A6ADRB2ASIC3LOXL2IDH1 | |
| SCHEMBL23032173 | 0.72 | CYP2A6 (0.49) | CYP2A6ADRB2ASIC3LOXL2AGXT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1363618-B1 | PHARMACEUTICAL COMPOSITION FOR TREATING MULTIPLE SCLEROSIS | NEU INGO S (DE) | 2006-05-03 | — | — | EP | claimed |
| US-20050020665-A1 | Pharmaceutical composition for treating multiple sclerosis | NEU INGO (DE) | 2005-01-27 | — | — | US | claimed |
| US-20110209699-A1 | COMBINATION OF DEHYDROEPIANDROSTERONE OR DEHYDROEPIANDROSTERONE-SULFATE WITH A LIPOXYGENASE INHIBITOR FOR TREATMENT OF ASTHMA OR CHRONIC OBSTRUCTIVE PULMONARY DISEASE | EPIGENESIS PHARMACEUTICALS, LLC | 2011-09-01 | — | — | US | disclosed |
| US-20050090455-A1 | Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a lipoxygenase inhibitor for treatment of asthma or chronic obstructive pulmonary disease | EPIGENESIS PHARMACEUTICALS, LLC. | 2005-04-28 | — | — | US | disclosed |
| US-20050043282-A1 | Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a lipoxygenase inhibitor for treatment of asthma or chronic obstructive pulmonary disease | EPIGENESIS PHARMACEUTICALS LLC | 2005-02-24 | — | — | US | disclosed |
| US-20050020665-A1 | Pharmaceutical composition for treating multiple sclerosis | NEU INGO (DE) | 2005-01-27 | — | — | US | disclosed |
| EP-0279263-B1 | INDOLE, BENZOFURAN, BENZOTHIOPHENE CONTAINING LIPOXYGENASE INHIBITING COMPOUNDS | ABBOTT LABORATORIES (US) | 1993-08-04 | — | — | EP | disclosed |
| US-4873259-A | Indole, benzofuran, benzothiophene containing lipoxygenase inhibiting compounds | ABBOTT LABORATORIES (US) | 1989-10-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050090455-A1 | Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a lipoxygenase inhibitor for treatment of asthma or chronic obstructive pulmonary disease | HSD11B2, CYP17A1, ALOX5 | CYP2A6 356/4885ADRB2 330/4885ASIC3 4278/4885 |
| US-20050020665-A1 | Pharmaceutical composition for treating multiple sclerosis | NR1H3, NR1H2, NR1H4 | CYP2A6 996/4885ADRB2 176/4885ASIC3 301/4885 |
| US-20050043282-A1 | Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a lipoxygenase inhibitor for treatment of asthma or chronic obstructive pulmonary disease | HSD11B2, CYP17A1, ALOX5 | CYP2A6 365/4885ADRB2 345/4885ASIC3 4340/4885 |
| US-20110209699-A1 | COMBINATION OF DEHYDROEPIANDROSTERONE OR DEHYDROEPIANDROSTERONE-SULFATE WITH A LIPOXYGENASE INHIBITOR FOR TREATMENT OF ASTHMA OR CHRONIC OBSTRUCTIVE PULMONARY DISEASE | HSD11B2, CYP17A1, ALOX5 | CYP2A6 356/4885ADRB2 330/4885ASIC3 4278/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.